BU-NOT-SET

CONTACT US
On the pathway to clinic, solubility remains one of the biggest hurdles: CDMO
  • Drug product
Eyes
Insight
US DSCSA: data standardisation
  • Manufacturing
Eyes
Insight
Developments in high-throughput screening
  • Drug product
Eyes
Insight
CDMOs and innovation: remaining competitive
  • Industry trends
Eyes
Insight
2018 Forecast: What to watch out for over the coming 12 months in pharma
  • Industry trends
Eyes
Insight
Pharmaceutical Manufacturing: one year until the EU FMD
  • Manufacturing
Eyes
Insight
Recipharm’s outlook: The evolution of the CDMO market
  • Industry trends
Eyes
Insight
CDMO services: Key drivers of growth
  • Drug product
  • Industry trends
woman at data screen
Insight
Preparing for track & trace | pharmaceutical serialization regulations
  • Manufacturing
Eyes
Insight
Case study
  • Drug product
Modified release fixed dose combination product with two poorly soluble drug substances
Insight
  • Drug product
Patient centricity during drug development and commercialisation
Insight
  • Drug product
10 considerations to kick-start your drug development journey
Insight
  • Drug product
Guidance for start-ups on drug development
White paper
  • Drug product
  • Drug substance
Drug development for start-ups
Insight
  • Sustainability
Optimising environmental sustainability
Insight
  • Industry trends
Adapting to deal with the COVID-19 pandemic
Insight
  • Sustainability
On Drug Delivery – Sustainability Q&A
Insight
  • Analytical chemistry
Optimising analytical chemistry to improve speed to market